癌症化疗耐药中的分子影像:正在酝酿什么?
本文综述SPECT、PET和光学成像在应对癌症化疗耐药中的应用,重点讨论ATP结合盒转运蛋白(尤其P-糖蛋白)过表达所致耐药的无创成像生物标志物需求,强调这些模态在早期识别耐药克隆和改进治疗策略方面的潜力,并概述分子影像融入临床实践所需的关键步骤。
要点
- 化疗耐药是乳腺癌、肺癌、卵巢癌、胰腺癌、膀胱癌、肉瘤和淋巴瘤等侵袭性癌症的主要挑战。
- ATP结合盒转运蛋白(尤其P-糖蛋白)过表达显著促成化疗耐药。
- 亟需成像生物标志物在体内检测P-糖蛋白过表达、识别耐药克隆并绘制瘤内分布与异质性。
核心结论
- 分子影像(SPECT、PET和光学成像)有望通过早期识别耐药克隆和改进治疗策略来增强癌症治疗。
- 文章概述了将分子影像融入临床实践以克服化疗耐药和优化患者结局所需的关键步骤。
研究设计与样本
- 本文为综述,总结SPECT、PET和光学成像在应对癌症化疗耐药方面的应用。
主要发现
- ATP结合盒转运蛋白(尤其P-糖蛋白)过表达显著促成化疗耐药。
- 亟需成像生物标志物在体内检测P-糖蛋白过表达、识别耐药癌细胞克隆并绘制其在肿瘤内的分布与异质性。
- 综述强调SPECT、PET和光学成像在早期识别耐药克隆和改进治疗策略方面的潜力。
临床怎么用
- 文章概述了将分子影像融入临床实践所需的关键步骤,旨在克服化疗耐药并优化患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for many aggressive cancers, including breast, lung, ovarian, pancreatic, bladder, sarcoma, and lymphomas. A major challenge is chemoresistance, in which cancer cells evade chemotherapy's cytotoxic effects. Overexpression of adenosine triphosphate-binding cassette transporters, especially P-glycoprotein, significantly contributes to this resistance. Thus, imaging biomarkers are urgently needed to detect P-glycoprotein overexpression in vivo, identify resistant cancer cell clones, and map their distribution and heterogeneity within tumors. This article reviews the applications of SPECT, PET, and optical imaging in addressing chemoresistance. It emphasizes the potential of these modalities to enhance cancer treatment by enabling early identification of resistant clones and improving therapeutic strategies. The article outlines key steps required for the integration of molecular imaging into clinical practice, aiming to overcome chemoresistance and optimize patient outcomes.
引用
- Urso L, Uccelli L, Boschi A, et al. Molecular Imaging in Cancer Chemoresistance: What's Brewing? J Nucl Med. 2025. PMID: 39915122. doi:10.2967/jnumed.124.268967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。